Indian Patent Board Orders More Data From Novartis In Glivec Appeal
This article was originally published in PharmAsia News
Executive Summary
Novartis, the Swiss drug maker, has been instructed to provide more information if it expects to win its appeal of a ruling against a patent for its Glivec (imatinib) blood-cancer drug. The Intellectual Property Appellate Board told Novartis to submit documents supporting its claim that a newer version of the drug enhanced its efficacy. Novartis is appealing a previous ruling rejecting its claim against generics proposed by Cipla, Natco Pharma and Ranbaxy Laboratories, in addition to the Cancer Patients' Aid Association. (Click here for more